Peripheral blood cell DNA from a patient with a chronic myeloproliferative disorder was tested in the tumorigenicity assay. Upon tumor induction in nude mice we isolated a human oncogene by means of genomic cloning, exon trap analysis and cDNA cloning. Sequence analysis revealed a fusion product of the p85b subunit of phosphatidylinositol (PI) 3-kinase and HUMORF8, a putative deubiquitinating enzyme, which has been generated during the DNA transfection process. Application of the tumorigenicity assay to various p85b and HUMORF8 cDNA constructs indicated that the recombination of both genes rather than the truncation of one of the fusion partners renders the chimeric protein tumorigenic. Moreover, sequence analysis of human wildtype p85b revealed an alanine for serine substitution at a site important for the regulation of the lipid kinase activity of PI 3-kinase in human p85a. This variation may relate to dierences in the mode of signal transduction from both p85 isoforms.
Introduction
DNA-mediated gene transfer has allowed the detection and cloning of oncogenes which have the ability to transform the NIH3T3 mouse ®broblast cell line (Wigler et al., 1979) . Genes identi®ed in this way play an essential role in the regulation of cell growth and tissue dierentiation and comprise members of various classes of signal transducers such as receptor tyrosine kinases, non-receptor serine/threonine kinases, growth factors and regulators of small G proteins.
Initially most oncogenes detected through the transfection of tumor DNA into NIH3T3 cells belonged to the ras family (Barbacid, 1987) . However, the development of various variants of the classical focus formation assay, namely the tumorigenicity assay (Fasano et al., 1984) , expression cDNA cloning (Miki et al., 1991) and expression cloning by retroviral transfer of cDNA libraries (Whitehead et al., 1995a) gradually led to the discovery of various other transforming genes including neu (Shih et al., 1981) , met (Cooper et al., 1984) , ret (Takahashi et al., 1985) , trk (Martin-Zanca et al., 1986) , raf (Shimizu et al., 1985) , dbl (Eva and Aaronson, 1985) , hst (Sakamoto et al., 1986) , mas (Young et al., 1986) , lca (Ochiya et al., 1986) , B-raf (Ikawa et al., 1988) , tre (Nakamura et al., 1988) , vav (Katzav et al., 1989) , hhc (Yang et al., 1990) , ufo/axl (Janssen et al., 1991; O'Bryan et al., 1991) , ect , mos (Wang et al., 1993) , cot/tpl-2 (Chan et al., 1993) , tim (Chan et al., 1994a) , TC21 (Chan et al., 1994b) , ost (Horii et al., 1994) , lbc (Toksoz and Williams, 1994) , FGF-8 (Lorenzi et al., 1995) , lfc (Whitehead et al., 1995b) , lsc (Whitehead et al., 1996) and NET1 (Chan et al., 1996) .
Phosphatidylinositol 3-kinases (PI 3-kinases) constitute a family of enzymes with homologous catalytic subunits and varied regulatory domains or subunits. Isoforms of PI 3-kinase comprise heterodimeric PI 3-kinases that are stimulated by the binding of regulatory SH2 domains to tyrosine phosphoproteins, an isoform (p110g) regulated by bg subunits from trimeric G proteins, a monomeric form homologous to the VPS-34 yeast PI 3-kinase, and isoforms containing C2 regulatory domains. The PI 3-kinases phosphorylate the D-3 position of the inositol ring of PI, PI 4-phosphate, and PI 4,5-biphosphate, which are found in membranes. The kinases exhibit dierent substrate speci®cities (reviewed in Kapeller and Cantley, 1994) . A number of other proteins have been identi®ed which show sequence similarity to the kinase domain of PI3Ks. These include the DNA dependent protein kinase, the ataxia telangiectasia mutated (ATM) gene, TOR-related proteins (TOR2/FRAP/RAFT) and the PI 4-kinases.
The heterodimeric PI 3-kinase is composed of a 110 kDa catalytic subunit (p110a or b) and a regulatory subunit of either 85 kDa (p85a or p85b), 55 kDa (p55 PIK or p55a; p85/AS53) or 50 kDa (p50a), respectively (reviewed in Carpenter and Cantley, 1996) . The p85 subunit contains one Src homology 3 (SH3) domain, a rho binding domain homologous to Bcr, two proline-rich SH3-binding motifs, and two SH2 domains. A p110 binding region is located between the two SH2 domains (inter-SH2 domain). The smaller regulatory subunits only contain the two SH2 domains together with the inter-SH2 domain. The SH2 domains in the p85 subunit of PI 3-kinase bind to tyrosine phosphorylated proteins that contain YXXM amino acid motifs, as e.g. cytoplasmic or receptor tyrosine kinases. Activation of PI 3-kinase has been associated with a number of biological eects, such as mitogenesis, membrane ruing, neurite outgrowth, vesicular tracing, protection from apoptosis and insulinstimulated glucose transport (reviewed in Kapeller and Cantley, 1994); Carpenter and Cantley, 1996; Franke et al., 1997; Toker and Cantley, 1997) .
Protein degradation, by the ubiquitin/proteasome dependent pathways is involved in the regulation of various biological processes, such as cell cycle progression, signal transduction, cell dierentiation, metabolic control, embryogenesis and oncogenesis. Enzymes that attach ubiquitin to proteins lead to a rapid destruction of targeted proteins, a process counter regulated by ubiquitin carboxy-terminal hydrolases. Deubiquitinating enzymes can be divided into two groups, one acts on small substrates, while the UCH2 subfamily interacts with large substrates. Members of this steadily expanding family are characterized by two small conserved functional domains, the Cys and His domains (Ciechanover, 1994; Hochstrasser, 1995) . They include two genes with oncogenic potential, tre-2 and unp (Papa and Hochstrasser, 1993; Gupta et al., 1994) . In this paper we describe for the ®rst time a tumorigenic version of the human p85b subunit based on fusion with HUMORF8, a deubiquitinating enzyme.
Moreover, sequence analysis of the p85b wild-type cDNA revealed an alanine for serine substitution at a site important for the regulation of the lipid kinase activity. This ®nding may relate to dierences in functional properties between p85 isoforms.
Results
Application of the tumorigenicity assay to peripheral blood cell DNA from a patient (SW) with chronic myeloproliferative disorder, resulted in the induction of tumors in nude mice. The oncogenic capacity was transferable into secondary and tertiary transfectants. Analysis of DNA from tertiary transfectants showed that they still harbored human repetitive sequences, implying that a human oncogene was responsible for the tumor induction (data not shown).
DNA of tertiary transfectants was cloned into the EMBL-3 phage vector and screened for human oncogenic sequences, using human`alu' repetitive sequences as probe. In this way we were able to isolate two human alu-positive phage clones, SW-1 and SW-12. DNA from these positive phages was used as a probe to hybridize a Northern blot containing RNA of tertiary transfectants from the patient (SW-transfectants), but we were not able to detect any signal. Therefore, a cDNA library was constructed from RNA of tertiary SW-transfectants and screened with the same probe, again with a negative result. To circumvent possible problems in the hybridization analysis, which could stem from the usage of complete phage DNA, we decided to take advantage of the exon-trapping strategy. Two genomic subfragments of 4.5 and 4.3 kb from an alu-positive phage clone, SW-1/25 and SW-1/38, were cloned in both orientations into the polylinker site of the pL53In exon trapping vector, residing in an intron between two insulin exons (Auch and Reth, 1990) . The resulting constructs were transfected into COS-7 cells and expressed transiently. RNA was isolated from the transfected COS-7 cells, transcribed into cDNA and PCR-ampli®ed using two speci®c exontrap insulin primers. One of the exon-trap constructs was found to be positive and revealed a PCR product of about 500 bp. The PCR product was cloned into a T-vector and sequenced with primers derived from the exon trap vector. Sequence comparison revealed highest homology with the bovine p85b subunit of phosphatidylinositol 3-kinase. (GenBank Acc. Nr. M61746). Subsequently, the cDNA library of a third cycle SW-transfectant was screened with this 500 bp exon-trap fragment as a probe and we were able to identify various positive plaques.
In order to discriminate between human and endogenous mouse p85b subunit clones and to ®nd out whether the`oncogenic' p85b subunit from SWtransfectants shows any alterations as compared to human wildtype p85b, we determined the wildtype p85b cDNA sequence in mouse and human, which had not been published at that time. Respective sequences have been submitted to the EMBL-database under the Acc. Nrs. X80907 and Y13569 for the human and mouse p85b subunit, respectively. Comparison between the protein sequences of the p85b isoforms from human, mouse, bovine and rat shows a high homology throughout their entire length. In addition we observed a high homology to the p85a isoforms from the amino-terminal SH2-domain to the carboxyterminus. Moreover, we noticed an alanine for serine substitution at amino acid 606 of p85b, a site important for the regulation of the lipid kinase activity of the p85a protein.
As expected, many clones isolated from the SWtransfectant cDNA library contained mouse p85b, but some of them also contained human p85b sequences. Comparison with human wildtype p85b cDNA revealed identity up to position 1753. The adjacent 3' sequences revealed homology to a gene, called HUMORF8 (Acc. Nr. D29956) ( Figure 1a ). The HUMORF8 gene has previously been identi®ed through the analysis of randomly sampled cDNA clones from the human immature myeloid cell line KG-1 (Nomura et al., 1994) . This gene shows homology to the human oncogene tre and contains Cys-and His-domains, characteristic for deubiquitinating enzymes (Figure 1b) . The hybrid cDNA consists of the 5' end of the human p85b gene fused to the 3' end of the HUMORF8 gene. Except for the carboxy terminal SH2 domain and adjacent inter-SH2 domain sequences, most parts of the human p85b gene are retained in the hybrid product. Regarding HUMORF8, the His and Cys domains, which represent the putative deubiquitinating activity of the protein, are present in the fusion transcript.
In order to con®rm these data, we performed Northern-and Southern blot as well as RT ± PCR analyses on SW-transfectants. Tertiary transfectants containing other human oncogenes among a mouse background as well as human cell lines were included as controls. The Northern blot analysis, performed with two dierent probes, is shown in Figure 2 . Figure 2a shows the hybridisation results with probe SW31 BglII containing HUMORF8 sequences. Figure  2b exhibits the rehybridization of the same ®lter with probe SW31 NarI/FspI containing P85b sequences. Both probes are located in close proximity to the recombination point. The hybridization pattern is rather complex due to various transcripts of similar size. In Figure 2a , both SW-transfectants show two dierent hybridization signals, A and B (Figure 2a , lanes 4 and 5). However, signal B is composed of the mouse HUMORF8 transcript (compare with lanes 2 and 3) and the human chimeric p85b/HUMORF8 transcript. Signal A in Figure 2a represents an alternatively spliced human chimeric p85b/HU-MORF8 transcript due to alternative splicing at the 3' end of the human HUMORF8 transcript (compare with lane 1). The p85b probe identi®es three dierent signals in SW-transfectants (Figure 2b , lanes 9 and 10). Signal A represents the alternatively spliced human p85b/HUMORF8 transcript mentioned above (lanes 9, very weak, and 10). Signal B represents the main human p85b/HUMORF8 transcript which has the same size as the normal human p85bmRNA (compare with lane 6). The mouse speci®c p85b transcript is depicted as signal C and can be observed in all four NIH3T3 cell derived transfectants ( Figure  2b , lanes 7 ± 10). The size of the mouse p85b transcript matches with the data from Pons et al. (1995) .
In order to determine whether the chimeric p85b/ HUMORF8 gene was already present in the initial DNA sample derived from patient SW, we performed Southern blots on the patient's DNA, a human pre-B leukemia cell line (KOPN-8) , the SW-transfectants and two other transfectants (Fr-T1A, Gi-T1A) with the two probes used in the Northern blot analysis ( Figure  3 ). KOPN-8 and the DNA of patient SW showed identical hybridization patterns (Figure 3a and b) . This implies a germline con®guration of both genes, p85b as well as HUMORF8, in the initial blood cell sample from the patient (Figure 3, lanes 1, 2 and 7,  8 ). In the SW-transfectants, two human HUMORF8 bands of 2.3 and 6.6 kb in addition to a mouse Figure 1 (a) Fusion of the human PI 3-kinase p85b subunit and the putative deubiquitinating enzyme HUMORF8. Base numbers of human p85b (accession number X80907) and HUMORF8 (accession number D29956) are indicated at the left and right site of the sequence, respectively. The corresponding amino acids are shown below the DNA sequence. The fusion point is marked by an arrow. Methods: DNA from a peripheral blood sample of a patient with chronic myeloproliferative disease was tested in the tumorigenicity assay as described previously (Janssen et al., 1985) . DNA isolated from a third-cycle SW-induced mouse tumor was cloned into the EMBL-3 phage vector and screened with a human Alu-probe (Janssen et al., 1991) . Genomic subfragments of alu-positive phages were subcloned into the SmaI site of the exon trapping vector pL53In and transiently transfected into COS-7 cells (Auch and Reth, 1990) . RT ± PCR analysis of the transfected COS-7 cells revealed a 500 bp ampli®cation product containing trapped exon sequences. Therefore a lambda gt10 cDNA library was constructed from poly(A) + RNA of a tertiary SW-transfectant and screened with the 500 bp exon trap fragment. Normal human p85b cDNA clones were isolated from a human fetal liver cDNA library (Clontech, Heidelberg, Germany). Respective clones were plaquepuri®ed and the insert DNA was cloned into the EcoRI site of the pT7T3 plasmid vector (Pharmacia, Freiburg, Germany). The nucleotide sequence was determined by the dideoxy chain termination method using double-stranded plasmid DNA and T7 DNA polymerase (Pharmacia). Sequence analysis was performed using the software package of the Genetics Computer Group (GCG) of the University of Wisconsin. (b) Structure of the chimeric protein identi®ed in SW-transfectants. Structures of the human p85b subunit of PI 3-kinase, the human HUMORF8, the chimeric p85b/HUMORF8 protein and two constructs, 5' p85b and 3' HUMORF8 are shown. The recombination points in the p85b and the HUMORF8 protein are marked by arrows. Cys (c) and His domains within HUMORF8 constructs are indicated -7  U937-T1G1  U937-T1F1  SW-T1B  SW-T1A  MCF-7  U937-T1G1  U937-T1F1  SW-T1B SW-T1A Figure 2 Northern blot analysis of SW-transfectants. RNA samples of the human mammary tumor cell line MCF-7 (lanes 1 and 6), two tertiary U937-transfectants containing a novel, still uncharacterized human oncogene, U937T1g1 (lane 2 and 7) and U937T1F1 (lanes 3 and 8), two secondary SW-transfectants SW-T1B (lanes 4 and 9) and SW-T1A (lanes 5 and 10) were loaded on a denaturing agarose gel, electrophoresed in the presence of formaldehyde and transferred to nylon membranes. Panel A was hybridized with a human HUMORF8-speci®c probe. The ®lter was stripped and rehybridized with a human p85b-speci®c probe (b). The signals A, B and C are explained in the text. 28S and 18S ribosomal RNA are indicated. Methods: Total RNA was isolated and puri®ed by acid guanidinium isothiocyanate phenol chloroform extraction as described (Chomczynski and Sacchi, 1987) . Northern blot analysis and stripping of the ®lters were performed as described by Shackleford and Varmus (1987) . Brie¯y, ten micrograms of total RNA were loaded on 1% agarose gels, blotted on Nytran 13N membranes (Schleicher and Schuell, Dassel, Germany). DNA and RNA ®lters were hybridized in 36SSC (0.45 M NaCl, 0.045 M sodium citrate), 56Denhardt's, 200 mg ml 71 denatured salmon sperm DNA, 1% SDS, and 10% dextran sulfate at 638C for 16 h. Filters were extensively washed in 36SSC, 0.1% SDS at 638C, followed by a wash at moderate or high stringency. Filters were exposed to Kodak XOmat DS ®lm at 7708C with Ilford intensi®er screens HUMORF8 DNA fragment of about 3.0 kb are detected (Figure 3a, lanes 3 and 4) . The detection of a mouse speci®c HUMORF8 fragment by a human probe (Figure 3a , lanes 5 and 6) indicates that HUMORF8 is evolutionarily conserved. This is in accordance with data from other deubiquitinating enzymes. Using a p85b probe, two rearranged human p85b fragments of about 1.8 and 2.2 kb can be found in DNAs of the two SW-transfectants (Figure 3b , lanes 9 and 10). Despite the sequence homology of 89.9% between mouse and human p85b in the region covered by the probe, no cross-hybridization with mouse DNA was observed (Figure 3b, lanes 11 and  12) . Secondary SW-T1A transfectants show stronger signals of the p85b/HUMORF8 fragments due to the ampli®cation of the oncogene in the course of the transfection analyses (Figure 3, lanes 4 and 10) .
Finally, RT ± PCR studies were performed to con®rm the presence of chimeric transcripts in SWtransfectants. RNA of three SW-transfectants and two other transfectants (U937-T2g2, HELT1b1), containing dierent human oncogenes in a mouse background, were transcribed into cDNA and ampli®ed with two primers¯anking the fusion point of the chimeric p85b/HUMORF8 transcript. Only SWtransfectants revealed the chimeric p85b/HUMORF8 product ( Figure 4a, lanes 2, 3 and 4) , while all the cDNAs scored positive for ampli®cation of the abl gene (Figure 4b) .
Since deubiquitinating enzymes, as e.g. tre-2 and unp, bear oncogenic capacity and PI 3-kinase plays an important role in signal transduction, both fusion partners may play a critical role in the malignant transformation of SW-transfectants. In order to address this issue in more detail, various constructs of the complete p85b and HUMORF8 cDNAs as well as those parts of the genes involved in the recombination process were established (Figure 1b) . These constructs were cloned into eukaryotic expression vectors, transfected into NIH3T3 cells and tested in nude mice. Table 1 shows, that the p85b/HUMORF8 chimeric constructs, induced tumors in nude mice with a short latency period. Neither the human 5' p85b nor the human 3' HUMORF8 construct were able to induce tumors per se. Single tumors were detected upon usage of the complete human p85b and HUMORF8 constructs, respectively. However, Northern blot analysis of these tumors did not reveal any expression of both constructs (data not shown). Thus either the mice developed spontaneous tumors or endogenous mouse sequences became activated during the transfection process. and 7) , patient SW (lanes 2 and 8), the primary SW-transfectant SW-T1 (lanes 3 and 9), the secondary SW-transfectant SW-T1A (lanes 4 and 10), a transfectant Fr-T1A, containing an activated human B-raf oncogene (lanes 5 and 11) and transfectant Gi-T1A, containing an activated human hst oncogene, were digested with the restriction endonuclease HindIII (Pharmacia), electrophoresed in 0.6% agarose gels and transferred to nylon membranes (Nytran, Schleicher and Schuell). Filters A and B were hybridized with the HUMORF8-speci®c BglII probe (a) and the p85b-speci®c NarI/FspI probe (b), respectively. Methods: DNA insert probes were gel puri®ed by Spin-X centrifugation (Vogelstein, 1987) and radiolabeled by random priming (T7 QuickPrime kit, Pharmacia) in the presence of 2 mM spermidine and hybridized as described in the legend to RT ± PCR analysis of chimeric p85b/HUMORF8 transcripts. Five micrograms of total RNA from the indicated transfectants (U937-T2g2 and HEL-T1b1 tertiary transfectants contain an activated human ret and cot oncogene, respectively) were transcribed into cDNA with random hexamers and the Superscript RT as recommended by the manufacturer (Gibco BRL, Eggenstein, Germany). One tenth of the cDNA reaction mixture was used for ampli®cation. cDNA reactions without added RNA were used as controls. Methods: Two of 20 ml cDNA synthesis reaction mixture was used in a 100 ml PCR reaction, that consisted of; 20 mM Tris/HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl 2 , 0.001% gelatin (w/v), 200 mM of each deoxynucleotide triphosphate, 40 pmoles primers and 1 U Taq polymerase (Amplitaq DNA Polymerase, Perkin Elmer Applied Biosystems, Weiterstadt, Germany). Ampli®cations were performed in an automated PCR processor (BioMed, Theres, Germany) as follows: 35 cycles comprising denaturation at 928C for 30 s, annealing at 568C for 60 s, primer extension at 728C for 90 s, with an initial denaturation step at 928 for 3 min, and a ®nal extension step at 728C for 10 min. PCR products were electrophoresed in a 2.5% agarose gel and stained with ethidium bromide. For the detection of the chimeric p85b/HUMORF8 transcript (a), the following primers were utilized; SW31-1542 sense (5'-tccggcgtgagggcaacg-3') and SW31-1942 antisense (5'-gtttcggttgaaataatcagcc-3') . In order to verify the cDNA quality, cDNAs were ampli®ed with primers speci®c for the human abl gene, which are also capable of amplifying mouse abl cDNA sequences: ABL/A2-5' (5'-cagcggccagtagcatctgactttg-3') and ABL/ A3-3'B (5'-ccatttttggtttgggcttcacaccattcc-3')
Discussion
The NIH3T3 transformation assay has allowed the identi®cation of several oncogenes. Some of them were already activated in the original tumors, whereas others became oncogenic during the transfection process. Dierent modes of oncogene activation have been characterized, such as gene ampli®cation, gene truncation, point mutations, insertion of strong promoter sequences, fusion of genes, or loss of genomic negative regulatory sequences. Here we describe a chimeric p85b/ HUMORF8 gene, that was generated during the transfection of DNA derived from a patient with a chronic myeloproliferative disorder. Tumor-induction experiments with various p85b and HUMORF8 cDNA constructs suggest that the tumorigenicity is based on the combination of distinct parts of both genes rather than on the truncation of one of the two fusion partners. Regarding p85b, only the carboxy-terminal SH2 domain and part of the inter-SH2 sequence are deleted in the chimeras. In fact, the 40 amino acids (residue 445 ± 485) in the inter-SH2 domain, that are required for the binding of the catalytic PI 3-kinase p110 subunit are unaected (Dhand et al., 1994a) . Therefore, signaling of PI 3-kinase through its speci®c phosphoinositide lipid products may remain intact and activate various downstream targets such as protein kinase C isomers, ras and akt (Carpenter and Cantley, 1996; Hemmings, 1997; Toker and Cantley, 1997) . As in wildtype p85b the BCR-homology region of the chimeric protein could interact with the GTPbound forms of rac and Cdc42 (Carpenter and Cantley, 1996) , while its proline-rich region and SH3 domain could bind abl, lck, lyn, fyn, dynamin, a, b and g tubulin, p36/38, GRB2, actinin, SHC, src, cbl, phosphoinositides and p85 to itself (Kapeller et al., 1994; 1995; Pleiman et al., 1994; Gout et al., 1993 , Susa et al., 1996 Fukazawa et al., 1995; Wang et al., 1995; Shibasaki et al., 1994; Harrison-Findik et al., 1995; Liu et al., 1993; Meisner et al., 1995) . Membrane localization of PI 3-kinase, either via N-terminal myristoylation or via C-terminal farnesylation signals, is sucient to stimulate downstream targets (Klippel et al., 1996) . Phosphotyrosine peptide binding to either SH2 domain or binding of a polyclonal antibody to the N-SH2 domain generates an intramolecular signal through the inter-SH2 region, which in turn activates allosterically p110 (Holt et al., 1994; McIlroy et al., 1997) . The HUMORF8 moiety might either localize the p85b/HUMORF8 chimeric protein to the membrane or change its con®guration in such a way that it stimulates the bound PI 3-kinase activity.
A major part of the HUMORF8 protein became deleted during the recombination process. However, the catalytic Cys-and His domains are preserved in the oncogenic fusion protein product. Thus, one could discuss a similar activation scenario for the deubiquitinating enzyme HUMORF8 as described above for the p85b subunit of PI 3-kinase. Alternatively, the truncated p85b or HUMORF8 versions of the chimeric protein may act in a dominant-negative fashion. Cases in point are the loss of function of the human tre-2 oncogene (Papa and Hochstrasser, 1993) and phospholipase Cg that cause malignant transformation (Whitehead et al., 1995a) . Chimeric p85b/HUMORF8 cDNA constructs exhibiting speci®c point mutations which inactivate either the PI 3-kinase or the deubiquitinating enzyme, may help to elucidate further the mechanism of activation. On the other hand we can not formally rule out that a slightly increased expression of either gene from the fusion product triggers transformation and tumor-induction.
Phosphorylation at serine 608 (p85a) of the p85 regulatory subunit through the catalytic p110 subunit regulates the lipid kinase activity of PI 3-kinase (Dhand et al., 1994b) . Loss of this serine residue in the chimeric transcript could render it insensitive for the regulation by lipid kinase and hence result in tumor induction. However, our data demonstrate that in contrast to bovine, rat and mouse p85b, the wildtype human p85b subunit of PI 3-kinase shows an alanine at this position. This variation may relate to dierences in the regulation of both p85 isoforms. For instance Reif et al. described, that the p85a subunit is constitutively phosphorylated at serine residues, whereas p85b shows a marked increase in threonine phosphorylation following T cell activation (Reif et al., 1993) .
Elucidation of the mode of activation in the p85b/ HUMORF8 gene is hampered by several factors such as the involvement of two potential oncogenes, the existence of various isoforms of both genes, their interaction with various other proteins and the complex mechanisms which regulate their enzymatic activity. Further experiments are in progress to answer these questions.
Note added in proof
The cDNA sequences of the human and murine p 85b subunit have been submitted to the EMBL-database under the ACC. Nos. X80907 and Y13569, respectively. Figure 1b , were cloned into the eukaryotic expression vector pCI (Promega, Mannheim, Germany). NIH3T3 cells were transfected with 2 mg construct DNA, 500 ng RSVneo selection plasmid and 17.5 mg mouse carrier DNA as described (see legend to Figure 1a ). After G418 selection, approximately 1610 6 cells were injected subcutaneously into athymic NMRI nude mice. 
